Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

Introducing endless RNA (eRNA™) — a new class of programmable medicines capable of expressing therapeutic proteins inside the body. Engineered to translate programmed genetic code and express proteins. Stable and long-lasting which does not trigger innate immunity. Built with natural and modified nucleotides that leverages modular coding region for infinite application versatility. Uses non-coding regions to control expression, stability, targeting, and more. Invented within Flagship Pioneering, the possibilities of this platform are nearly unlimited, with applications that have the potential to replace or augment virtually every drug modality currently in use.